Bladder/Kidney/Other Urologic Cancers

Diabetes Treatments Compared for Bladder Cancer Risk

By July 17, 2017

The greatest incidence of bladder cancer was among the group who initiated pioglitazone treatment, in which there were 308 cases per 100,000 person-years.

Existing Treatment Effective in Bile Duct CA Following Surgery

May 22, 2017

In the per-protocol analysis, the researchers found that the average survival after surgery for those receiving capecitabine was 53 months, compared to 36 months for those who only had surgery. Existing Treatment Should be Considered Standard of Care in Biliary Cancer

Keytruda Approved to Treat Urothelial Carcinoma

By May 18, 2017

In addition, the FDA has granted accelerated approval for use in patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.

E-Cigarette Use May Up Bladder Cancer Risk

By May 15, 2017

The researchers believe that based on their findings, e-cigarette smokers may be at increased risk for bladder cancer.

Bavencio Gets Accelerated Approval for Urothelial Carcinoma

By May 09, 2017

Safety and efficacy of Bavenico was evaluated in the JAVELIN study that included 242 patients who were followed for a minimum of both 13 weeks and 6 months at the time of data cut-off.

Imfinzi Gets Accelerated Approval for Urothelial Carcinoma

By May 01, 2017

The confirmed ORR was 26.3% in patients with a high PD-L1 score (n=95) and 4.1% in patients with a low or negative PD-L1 score (n=73).

Amneal Introduces New Strength of Thiotepa with Tepadina

By April 27, 2017

Tepadina, an alkylating agent, is indicated to reduce the risk of graft rejection when used with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia.

FDA Gives Green Light to Stivarga HCC Indication

By April 27, 2017

A trial involving 573 patients with HCC whose tumors progressed after receiving sorafenib demonstrated the safety and efficacy of Stivarga in this population.

Tecentriq Approval Expands Use for Advanced Bladder Cancer

By April 18, 2017

Prior to this, Tecentriq was approved for use in locally advanced or mUC in patients with disease progression during or following any platinum-containing chemotherapy, or within 12 months of receiving chemotherapy before or after surgery.

Massage Improves Pain, Lymphedema in Female CA Patients

March 10, 2017

The researchers found that all participants reported a positive experience with aromatherapy massage.

CDC: Cancer Screening 'Considerably' Below Targets

March 07, 2017

The researchers found that screening test use remained considerably below HP2020 targets for selected cancer screening tests.

Avelumab Gets Priority Review for Urothelial Carcinoma Indication

By March 01, 2017

The FDA has accepted and granted Priority Review to the Biologics License Application (BLA) for avelumab (Merck and Pfizer) for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) with disease progression on or after platinum-based therapy.

Antibiotics May Negatively Impact Patients on Certain Cancer Drugs

February 17, 2017

Progression-free survival down with antibiotic use for patients receiving immune checkpoint inhibitors

Strategies to Improve HCC Screening in Cirrhosis Patients Compared

February 08, 2017

Outreach strategies increase the percentage of patients with cirrhosis who undergo hepatocellular carcinoma (HCC) screening.

FDA Grants Opdivo Accelerated Approval For Urothelial Carcinoma

By February 03, 2017

The FDA has approved Opdivo (nivolumab; Bristol-Myers Squibb) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or after platinum-based chemotherapy or for those who have disease progression within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy.

Positive Signs for Androgen Inhibition as Bladder CA Tx

January 23, 2017

For men with bladder cancer, androgen suppression therapy may be prophylactic for intravesical recurrence, according to a study published in the February issue of The Journal of Urology.

Work-Related Stress May Be Tied to Certain Cancers

By January 17, 2017

Prolonged work-related stress in men has been tied to increased chances of cancer at five sites; lung, colon, rectal, stomach and lymphatic.

Tecentriq Granted Priority Review for mUC Indication

By January 09, 2017

Genentech announced that the Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab)

Invasive Bladder CA Tied to Loss of Key Enzyme

December 15, 2016

Loss of argininosuccinate synthetase 1 (ASS1), a key enzyme for arginine synthesis, occurs in invasive bladder cancer, according to a study published online in The American Journal of Pathology.

FDA: Diabetes Drug Linked to Bladder Cancer Risk

By December 12, 2016

Healthcare professionals should not use the drug in patients with active bladder cancer and should carefully consider the risks and benefits prior to using it in patients with a history of bladder cancer.

Hallucinogenic Drug Reduces Anxiety, Depression in Distressed Cancer Patients

By December 01, 2016

A single moderate-dose of psilocybin (a hallucinogenic compound contained in psychedelic mushrooms) was found to produce enduring anxiolytic and antidepressant effects in distressed cancer patients with life-threatening diagnoses.

Experimental Drug Regimen Displays Robust Tumor Control in Kidney CA

December 01, 2016

The experimental drug CB-839 shows promise in treating kidney cancer, according to research presented at an international oncology conference in Munich on Wednesday.

Homeostasis Model Assessment Linked to HCC in Hep B Patients

November 18, 2016

Insulin resistance assessed by homeostasis model assessment index (HOMA2-IR) correlates with the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) infection, according to a study published online in the Journal of Gastroenterology and Hepatology.

Bladder CA and Vitamin D Levels: Is There a Correlation?

November 09, 2016

Low vitamin D levels may increase the risk of bladder cancer, according to a review presented at the annual meeting of the Society for Endocrinology.

Is Vit D Deficiency Tied to Higher Risk of Bladder Cancer?

By November 07, 2016

Patients who were vitamin D deficient had an increased risk of developing bladder cancer, a systematic review presented at the Society for Endocrinology annual conference has concluded.

FDA to Review Opdivo for Urothelial Carcinoma Use

By October 24, 2016

Bristol-Myers Squibb announced that the Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) for Priority Review.

Study Assesses Correlation Between Weight and Liver Cancer Risk

October 17, 2016

Having a large waistline, a high body mass index (BMI), and type 2 diabetes may raise risk for liver cancer, according to research published online October 14 in Cancer Research.

Survival Rates in Renal-Cell CA Assessed With Sunitinib Treatment

October 11, 2016

The duration of disease-free survival is increased with sunitinib treatment for patients with locoregional, high-risk clear-cell renal-cell carcinoma, according to a study published online in the New England Journal of Medicine.

FDA Modifies Dosing Regimen for Nivolumab

By September 15, 2016

The Food and Drug Administration (FDA) has approved a modification to the nivolumab (Opdivo; Bristol-Myers Squibb) dosage regimen for renal cell carcinoma, metastatic melanoma, and non-small cell lung cancer.

FDA Committee Says Bladder Cancer Drug Lacks Substantial Efficacy Evidence

By September 15, 2016

Spectrum announced that the Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted that Qapzola (apaziquone) has not shown substantial evidence of a treatment effect vs. placebo for immediate intravesical instillation post-transurethral resection of bladder tumors (post-TURBT) in patients with non-muscle invasive bladder cancer.